Thank you for your interest in the PROOF clinical research trial.
If you or someone you love has been diagnosed with cholangiocarcinoma, you may be interested in finding out more about the PROOF Trial. The PROOF Trial is evaluating an investigational drug—infigratinib—for patients who have advanced/metastatic or inoperable cholangiocarcinoma. Infigratinib is being tested as a once-daily oral alternative to chemotherapy.
Participants may be eligible if they:
- Are at least 18 years of age
- Have confirmed advanced/metastatic or inoperable cholangiocarcinoma
There are additional eligibility criteria for this trial, which the study doctor will discuss with you. Ask your doctor if you or your loved one may be eligible to enroll.
Infigratinib—oral, once daily
Intravenous gemcitabine with cisplatin